{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05047536",
            "orgStudyIdInfo": {
                "id": "KZR-261-101"
            },
            "organization": {
                "fullName": "Kezar Life Sciences, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "KZR-261 in Subjects With Advanced Solid Malignancies",
            "officialTitle": "A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "kzr-in-subjects-with-advanced-solid-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-09-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-09-03",
            "studyFirstSubmitQcDate": "2021-09-11",
            "studyFirstPostDateStruct": {
                "date": "2021-09-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Kezar Life Sciences, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK) of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprises a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors (melanoma/uveal melanoma, mesothelioma, colorectal cancer, prostate cancer, and \"All-Tumors\").",
            "detailedDescription": "The first-in-human, open-label, multicenter, Phase 1 study of KZR-261, Study KZR-261-101, will be conducted in two parts (dose escalation and dose expansion) to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of KZR-261 in subjects with locally advanced or metastatic solid malignancies for whom no therapeutics are available that can confer a reasonable likelihood of clinical benefit. The 5 tumor cohorts in the dose expansion part include advanced malignant:\n\n* melanoma/uveal melanoma\n* mesothelioma\n* colorectal cancer\n* castrate-resistant prostate cancer\n* \"All-Tumors\"\n\nPart 1 (Dose Escalation) and Part 2 (Dose Expansion) comprise a 4-week Screening Period, a Treatment Period lasting approximately 24 weeks, 4-6-week Safety Follow-up, and a 12-month Long-Term Follow-up Period (after last dose of study treatment), for a total study duration of approximately 20 months."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced/Metastatic Solid Tumor"
            ],
            "keywords": [
                "melanoma",
                "uveal melanoma",
                "colorectal cancer",
                "prostate cancer",
                "mesothelioma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "All subjects will receive 30 to 60-minute intravenous infusion of KZR-261 via a central line on Days 1, 8, and 15 of a 4-week (28-day) treatment cycle.\n\nUp to approximately 50 subjects will be enrolled and treated with KZR-261 in Part 1 (Dose Escalation). In Part 2 (Dose Expansion), up to 175 subjects (15-35 per tumor cohort \\[melanoma, uveal melanoma, colorectal cancer, prostate cancer, mesothelioma, and \"All-Tumor\"\\]) will be enrolled.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 225,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "KZR-261 with standard therapy: open-label",
                    "type": "EXPERIMENTAL",
                    "description": "Part 1 (Dose Escalation)\n\nThe initial dose cohort of the Dose Escalation will receive 1.8 mg/m2 of KZR-261. Subjects will receive 3 doses in a 28-day cycle.\n\n___________________________________________\n\nPart 2 (Dose Expansion)\n\nFollowing safety review of all Dose Escalation cohorts and determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD), KZR-261 will be evaluated for safety and preliminary efficacy in 4 tumor-specific cohorts and 1 all-tumor cohort to determine the recommended phase 2 dose (RP2D). The 4 tumor-specific cohorts will include:\n\n* melanoma (including uveal melanoma)\n* colorectal cancer\n* prostate cancer\n* mesothelioma",
                    "interventionNames": [
                        "Drug: KZR-261"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "KZR-261",
                    "description": "KZR-261 for Injection is a lyophilized drug product supplied in single-use vials delivering 75 mg of KZR-261.",
                    "armGroupLabels": [
                        "KZR-261 with standard therapy: open-label"
                    ],
                    "otherNames": [
                        "KZR-261 for Injection"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number and percentage of participants experiencing adverse events as assessed by CTCAE v5.0 (Part 1 & 2)",
                    "description": "Incidence and percentage of adverse events and serious adverse events will be collected from start of enrollment",
                    "timeFrame": "Approximately 20 months"
                },
                {
                    "measure": "Number and percentage of participants experiencing dose-limiting toxicities as assessed by CTCAE v5.0 (Part 1)",
                    "description": "Incidence and percentage of dose-limiting toxicities will be collected from start of enrollment",
                    "timeFrame": "Approximately 20 months"
                },
                {
                    "measure": "Maximum plasma concentration of KZR-261 (Part 1)",
                    "description": "Summary of maximum plasma concentration (Cmax) will be assessed",
                    "timeFrame": "Approximately 20 months"
                },
                {
                    "measure": "The plasma concentration time curve of KZR-261 (Part 1)",
                    "description": "Summary of the plasma concentration time curve (AUC) will be assessed",
                    "timeFrame": "Approximately 20 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Objective Response Rate (ORR) of KZR-261",
                    "description": "Defined as the rate of partial responses (PRs) plus complete responses (CRs) according to RECIST v1.1",
                    "timeFrame": "Approximately 20 months"
                },
                {
                    "measure": "Duration of response (DOR) of KZR-261",
                    "description": "Duration of overall response (partial response and complete response)",
                    "timeFrame": "Approximately 20 months"
                },
                {
                    "measure": "Progression-free Survival of Patients treated with KZR-261",
                    "description": "Time to disease progression",
                    "timeFrame": "Approximately 20 months"
                },
                {
                    "measure": "Overall Survival of Patients treated with KZR-261",
                    "description": "Time of overall survival",
                    "timeFrame": "Approximately 20 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic or cytologic evidence of malignant solid tumor with advanced disease (except primary central nervous system \\[CNS\\] neoplasms), defined as cancer that is either metastatic or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered to result in reasonable clinical benefit).\n* Disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the Investigator's judgement likely to result in clinical benefit, or if such therapy has been refused by the subject. Documentation of the reason must be provided for subjects who have not received a standard therapy likely to result in clinical benefit.\n* Eastern Cooperative Oncology Group Performance Status score of 0 or 1.\n* Adequate baseline hematologic and organ function.\n* Willing to use contraception.\n\nAdditional Inclusion for Part 2: Histologic or cytologic evidence of malignancy (melanoma/uveal melanoma, colorectal cancer, prostate cancer, mesothelioma).\n\nExclusion Criteria:\n\n* Subjects who have participated in Part 1 dose escalation are not eligible to enroll in Part 2 dose expansion.\n* Persistent clinically significant toxicities from previous anticancer therapy (excluding alopecia).\n* Treatment with cytotoxic, biologic, or targeted therapies for advanced cancer within 14 days before administration of the subject's first dose of KZR-261.\n* Treatment with an investigational drug within 28 days before administration of the subject's first dose of KZR-261.\n* Radiation therapy within 14 days of before administration of the subject's first dose of KZR-261.\n* Major surgical procedure within 28 days before administration of the subject's first dose of KZR-261.\n* History of risk factors for Torsades de pointes.\n* Active, symptomatic CNS metastases or primary CNS malignancy.\n* Any female who is breastfeeding or who plans to become pregnant during the study, or who are actively trying to conceive at the time of signing of the informed consent form (ICF).\n* Uncontrolled, clinically significant pulmonary disease.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Operations",
                    "role": "CONTACT",
                    "phone": "650-822-5600",
                    "email": "clinicaltrials@kezarbio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Kezar Study Director",
                    "affiliation": "Kezar Life Sciences, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Cedars Sinai Medical Center",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90048",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alain Mita, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "University of California Los Angeles",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bartosz Chmielowski, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Moffitt Cancer Center",
                    "status": "RECRUITING",
                    "city": "Tampa",
                    "state": "Florida",
                    "zip": "33612",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tiago Biachi de Castria, MD, PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 27.94752,
                        "lon": -82.45843
                    }
                },
                {
                    "facility": "Winship Cancer Institute of Emory University",
                    "status": "RECRUITING",
                    "city": "Atlanta",
                    "state": "Georgia",
                    "zip": "30322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "R. Donald Harvey, Pharm D",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.749,
                        "lon": -84.38798
                    }
                },
                {
                    "facility": "University Hospitals - Cleveland Medical Center",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44106",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Amit Mahipal, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Fox Chase Cancer Center",
                    "status": "RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19111",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Anthony Olszanski, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                },
                {
                    "facility": "Sara Cannon Research Institution (SCRI) - Tennessee Oncology Nashville",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Meredith McKean, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "START (South Texas Accelerated Research Therapeutics)",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Kyriakos Papadopoulos, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Virginia Cancer Specialists (VCS)",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Spira, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Kezar Life Sciences, Inc. corporate website",
                    "url": "http://www.kezarlifesciences.com/"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M11634",
                    "name": "Mesothelioma",
                    "relevance": "LOW"
                },
                {
                    "id": "M2537",
                    "name": "Mesothelioma, Malignant",
                    "relevance": "LOW"
                },
                {
                    "id": "T3099",
                    "name": "Intraocular Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T3584",
                    "name": "Malignant Mesothelioma",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}